Episode
Tavapadon as Adjunctive Therapy for Parkinson Disease - TEMPO-3 Trial
- Podcast
- Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology
- Published
- May 24, 2026
- Duration seconds
- 970
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/episodes/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
The provided sources detail phase 3 clinical trial results for tavapadon , a novel, once-daily dopamine D1/D5 receptor agonist designed to treat Parkinson disease . In the TEMPO-1 study, fixed doses of the medication significantly improved motor function and daily living experiences for patients in the early stages of the disease. Simultaneously, the TEMPO-3 trial demonstrated that tavapadon effectively increases "good-on-time" and reduces daily "off-time" when used as an add-on therapy for patients experiencing fluctuations while on levodopa . Researchers observed that the drug's selective targeting of specific receptors aims to minimize the side effects , such as hallucinations or impulse control issues, often linked to traditional dopamine agonists. Across both studies, tavapadon maintained a favorable safety profile , with most adverse events being mild to moderate in severity. These findings suggest that tavapadon offers a clinically meaningful new option for managing symptoms throughout different phases of the condition.